BeiGene Terezumab has been approved by the European Commission for the treatment of non-small cell lung cancer
Ronan62054
发表于 2024-4-25 16:29:05
1296
0
0
On April 25th, Southern Finance and Economics reported that the European Commission has approved the use of BeiGene Terezumab for first-line and second-line treatment of three indications for non-small cell lung cancer (NSCLC). This approval is the second approval obtained for rituximab in the European Union. Its indications for esophageal cancer have been approved in the EU in September 2023 and approved for market by the Food and Drug Administration (FDA) in March 2024. Tirelizumab is the first domestic product to go global in the PD - (L) 1 field, and it is also another self-developed core product of BeiGene after its BTK inhibitor Zebutinib. In addition to being approved for different indications in the EU region, it has also been approved in the UK, the US, South Korea, and Switzerland. (21st Century Business Herald)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Guozheng International: Yum! Brands China is resilient enough to weather the cycle
- General Motors China President: The unique innovation in the Chinese market brings many excellent opportunities
- Ericsson China President Fang Ying: CIIE provides a shared innovation platform for global enterprises
- The Nasdaq China Golden Dragon Index closed down 1.83%, with most popular Chinese concept stocks falling
- Jin Fangqian, Global Vice President of Gilead Sciences: Continue to increase investment in China and bring Chinese innovative drugs to the world
- Abbott brings multiple specialty foods to participate in the 7th CIIE, promoting China's silver economy
- Abbott announces the launch of its new women's health drug Fenyouning in China
- Sony releases' Sony China Sustainable Development Report '
- 2024 Enter the Expo | Improve local innovation ability, Nike digs gold in China's running market
- The spillover effect of the CIIE drives Sanofi's China business to accelerate and deepen its localization layout
-
第7回博覧会の開幕当日、11月5日、ファイザーは革新薬のトルエンスルホン酸タラゾールパッリカプセル(商品名:テゼナ)が先日、国家薬監局(NMPA)の承認を得て発売されたと発表した。それはエンザルアミンと共同 ...
- 了看允侥
- 8 小时前
- 支持
- 反对
- 回复
- 收藏
-
何思文氏は、「進博会というプラットフォームでは、私たちが始めたのは耳を傾けるモデルであり、進博会を通じて各種製品を展示し、消費者の需要とフィードバックを集め、将来中国に輸入する製品を決定するのに役立 ...
- an7en
- 8 小时前
- 支持
- 反对
- 回复
- 收藏
-
【エイダ氏は元NASA宇宙センター主任を取締役会メンバーに任命】エイレンオチョア氏はNASAのベテラン、エレン・オチョア氏を取締役に任命し、取締役会の規模は13人に拡大した。英偉達氏は声明の中で、66歳のオチョ ...
- 柔柔树呆熊呆j
- 11 小时前
- 支持
- 反对
- 回复
- 收藏
-
ハイエンド機能性アパレルブランドのCanada Gooseカナダガチョウは、2024年9月29日現在の2025年度第2四半期決算を発表した。 「私たちが直面しているマクロ経済環境はますます厳しくなり、消費者感情が影響を受けて ...
- 薇唯玮味
- 3 小时前
- 支持
- 反对
- 回复
- 收藏